Online inquiry

IVTScrip™ mRNA-Anti-TNF, CDP870(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5648MR)

This product GTTS-WQ5648MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, CDP870(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ5648MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ15877MR IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA XMT-1536
GTTS-WQ13005MR IVTScrip™ mRNA-Anti-CSF3R, PEG-G-CSF(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PEG-G-CSF
GTTS-WQ14945MR IVTScrip™ mRNA-Anti-PDCD1, SHR-1210(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SHR-1210
GTTS-WQ3043MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ1762MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ADCT-301
GTTS-WQ11021MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MCLA-117
GTTS-WQ3040MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ14525MR IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA SA-237
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW